The response of VEGF-stimulated endothelial cells to angiostatic molecules is substrate-dependent

BMC Cell Biology

Volumn 6, Issue , 2005, Pages

  Addison, Christina L ^a,c   Nör, Jacques E ^b   Zhao, Huijun ^a   Linn, Stephanie A ^c   Polverini, Peter J ^c   Delaney, Christie E ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 8; COLLAGEN TYPE 1; ENDOSTATIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; PROTEIN BCL 2; THROMBOSPONDIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; CASPASE; SCLEROPROTEIN; THROMBOSPONDIN 1; VASCULOTROPIN A;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR MECHANICS; PROTEIN EXPRESSION; CYTOLOGY; DRUG EFFECT; METABOLISM; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CASPASES; CELL PROLIFERATION; CELLS, CULTURED; CHEMOKINE CXCL10; COLLAGEN TYPE I; ENDOSTATINS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX PROTEINS; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 27744461681     PISSN: 14712121     EISSN: 14712121     Source Type: Journal    
DOI: 10.1186/1471-2121-6-38     Document Type: Article

References (66)

1. Gimbrone MA, Jr., Leapman SB, Cotran RS, Folkman J: Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972, 136:261-276.
2. Baenziger NL, Brodie GN, Majerus PW: Isolation and properties of a thrombin-sensitive protein of human platelets. J Biol Chem 1972, 247:2723-2731.
3. Dixit VM, Haverstick DM, O'Rourke KM, Hennessy SW, Grant GA, Santoro SA, Frazier WA: A monoclonal antibody against human thrombospondin inhibits platelet aggregation. Proc Natl Acad Sci U S A 1985, 82:3472-3476.
4. Leung LL: Role of thrombospondin in platelet aggregation. J Clin Invest 1984, 74:1764-1772.
5. O'Shea KS, Dixit VM: Unique distribution of the extracellular matrix component thrombospondin in the developing mouse embryo. J Cell Biol 1988, 107:2737-2748.
6. Taraboletti G, Roberts D, Liotta LA, Giavazzi R: Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 1990, 111:765-772.
7. Guo N, Krutzsch HC, Inman JK, Roberts DD: Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 1997, 57:1735-1742.
8. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N: Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 2000, 6:41-48.
9. Nor JE, Mitra RS, Sutorik MM, Mooney DJ, Castle VP, Polverini PJ: Thrombospondin-1 induces endothelial cell apoptosis and inhibits angiogenesis by activating the caspase death pathway. J Vasc Res 2000, 37:209-218.
10. Castle V, Varani J, Fligiel S, Prochownik EV, Dixit V: Antisense-mediated reduction in thrombospondin reverses the malignant phenotype of a human squamous carcinoma. J Clin Invest 1991, 87:1883-1888.
11. Castle VP, Dixit VM, Polverini PJ: Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells. Lab Invest 1997, 77:51-61.
12. Rastinejad F, Polverini PJ, Bouck NP: Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell 1989, 56:345-355.
13. Sheibani N, Frazier WA: Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci USA 1995, 92:6788-6792.
14. Luster AD, Ravetch JV: Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987, 166:1084-1097.
15. Sarris AH, Esgleyes-Ribot T, Crow M, Broxmeyer HE, Karasavvas N, Pugh W, Grossman D, Deisseroth A, Duvic M: Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma? [see comments]. Blood 1995, 86:651-658.
16. Taub DD, Longo DL, Murphy WJ: Human interferon-inducible protein-10 induces mononuclear cell infiltration in mice and promotes the migration of human T lymphocytes into the peripheral tissues and human peripheral blood lymphocytes-SCID mice. Blood 1996, 87:1423-1431.
17. Strieter RM, Kunkel SL, Arenberg DA, Burdick MD, Polverini PJ: Interferon gamma-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. Biochem Biophys Res Commun 1995, 210:51-57.
18. Angiolillo AL, Sgadari C, Taub DD, Liao F, Farber JM, Maheshwari S, Kleinman HK, Reaman GH, Tosato G: Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995, 182:155-162.
19. Arenberg DA, Kunkel SL, Polverini PJ, Morris SB, Burdick MD, Glass MC, Taub DT, Iannettoni MD, Whyte RL, Strieter RM: Interferon- gamma-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996, 184:981-992.
20. Feldman AL, Friedl J, Lans TE, Libutti SK, Lorang D, Miller MS, Turner EM, Hewitt SM, Alexander HR: Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002, 99:149-153.
21. Regulier E, Paul S, Marigliano M, Kintz J, Poitevin Y, Ledoux C, Roecklin D, Cauet G, Calenda V, Homann HE: Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Ther 2001, 8:45-54.
22. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
23. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen BR: Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. Embo J 1999, 18:4414-4423.
24. Taddei L, Chiarugi P, Brogelli L, Cirri P, Magnelli L, Raugei G, Ziche M, Granger HJ, Chiarugi V, Ramponi G: Inhibitory effect of full-length human endostatin on in vitro angiogenesis. Biochem Biophys Res Commun 1999, 263:340-345.
25. Dhanabal M, Ramchandran R, Waterman MJ, Lu H, Knebelmann B, Segal M, Sukhatme VP: Endostatin induces endothelial cell apoptosis. JBiol Chem 1999, 274:11721-11726.
26. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL: Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci U S A 2000, 97:4802-4807.
27. Perletti G, Concari P, Giardini R, Marras E, Piccinini F, Folkman J, Chen L: Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res 2000, 60:1793-1796.
28. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M, Singhal A, Sullivan S, Rolland A, Ralston R, Min W: Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 1999, 17:343-348.
29. Lochter A, Bissell MJ: Involvement of extracellular matrix constituents in breast cancer. Semin Cancer Biol 1995, 6:165-173.
30. Noel A, Kebers F, Maquoi E, Foidart JM: Cell-cell and cell-matrix interactions during breast cancer progression. Curr Top Pathol 1999, 93:183-193.
31. Nor JE, Christensen J, Mooney DJ, Polverini PJ: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999, 154:375-384.
32. Nor JE, Christensen J, Liu J, Peters M, Mooney DJ, Strieter RM, Polverini PJ: Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001, 61:2183-2188.
33. Feng X, Clark RA, Galanakis D, Tonnesen MG: Fibrin and collagen differentially regulate human dermal microvascular endothelial cell integrins: stabilization of alphav/beta3 mRNA by fibrin1. J Invest Dermatol 1999, 113:913-919.
34. Kanda S, Tomasini-Johansson B, Klint P, Dixelius J, Rubin K, Claesson-Welsh L: Signaling via fibroblast growth factor receptor-1 is dependent on extracellular matrix in capillary endothelial cell differentiation. Exp Cell Res 1999, 248:203-213.
35. Isik FF, Gibran NS, Jang YC, Sandell L, Schwartz SM: Vitronectin decreases microvascular endothelial cell apoptosis. J Cell Physiol 1998, 175:149-155.
36. Luscinskas FW, Lawler J: Integrins as dynamic regulators of vascular function. Faseb J 1994, 8:929-938.
37. Ingber DE: Extracellular matrix as a solid-state regulator in angiogenesis: identification of new targets for anti-cancer therapy. Semin Cancer Biol 1992, 3:57-63.
38. Thorburn A: Death receptor-induced cell killing. Cell Signal 2004, 16:139-144.
39. Bantel H, Engels IH, Voelter W, Schulze-Osthoff K, Wesselborg S: Mistletoe lectin activates caspase-8/FLICE independently of death receptor signaling and enhances anticancer drug-induced apoptosis. Cancer Res 1999, 59:2083-2090.
40. Inman GJ, Allday MJ: Apoptosis induced by TGF-beta 1 in Burkitt's lymphoma cells is caspase 8 dependent but is death receptor independent. J Immunol 2000, 165:2500-2510.
41. Vogel T, Guo NH, Krutzsch HC, Blake DA, Hartman J, Mendelovitz S, Panet A, Roberts DD: Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem 1993, 53:74-84.
42. Galvin NJ, Vance PM, Dixit VM, Fink B, Frazier WA: Interaction of human thrombospondin with types I-V collagen: direct binding and electron microscopy. J Cell Biol 1987, 104:1413-1422.
43. Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP: Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat Med 2002, 8:349-357.
44. Jackson CJ, Nguyen M: Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. Int J Biochem Cell Biol 1997, 29:1167-1177.
45. Geiger M, Stone A, Mason SN, Oldham KT, Guice KS: Differential nitric oxide production by microvascular and macrovascular endothelial cells. Am J Physiol 1997, 273:L275-281.
46. Mason JC, Yarwood H, Sugars K, Haskard DO: Human umbilical vein and dermal microvascular endothelial cells show heterogeneity in response to PKC activation. Am J Physiol 1997, 273:C1233-1240.
47. Luster AD, Greenberg SM, Leder P: The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med 1995, 182:219-231.
48. Yang J, Richmond A: The angiostatic activity of interferon-inducible protein-10/CXCL10 in human melanoma depends on binding to CXCR3 but not to glycosaminoglycan. Mol Ther 2004, 9:846-855.
49. Sbaa-Ketata E, Vasse M, Lenormand B, Schneider P, Soria C, Vannier JP: Fibronectin increases the migration induced by stromal cell-derived factor-1 alpha (SDF-1 alpha) in pre-B acute lymphoblastic leukemia cells. Eur Cytokine Netw 2001, 12:223-230.
50. Dixelius J, Larsson H, Sasaki T, Holmqvist K, Lu L, Engstrom A, Timpl R, Welsh M, Claesson-Welsh L: Endostatin-induced tyrosine kinase signaling through the Shb adaptor protein regulates endothelial cell apoptosis. Blood 2000, 95:3403-3411.
51. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, Kim KW, Lee ST, Kwon YG: Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000, 60:5410-5413.
52. Wickstrom SA, Veikkola T, Rehn M, Pihlajaniemi T, Alitalo K, Keski-Oja J: Endostatin-induced modulation of plasminogen activation with concomitant loss of focal adhesions and actin stress fibers in cultured human endothelial cells. Cancer Res 2001, 61:6511-6516.
53. Ergun S, Kilic N, Wurmbach JH, Ebrahinmejad A, Fernando M, Sevinc S, Kilic E, Chalajour F, Fiedler W, Lauke H, Lamszus K, Hammerer P, Weil J, Herbst H, Folkman J: Endostatin inhibits angiogenesis by stabilization of newly formed endothelial tubes. Angiogenesis 2001, 4:193-206.
54. Dhanabal M, Volk R, Ramchandran R, Simons M, Sukhatme VP: Cloning, expression, and in vitro activity of human endostatin. Biochem Biophys Res Commun 1999, 258:345-352.
55. Karumanchi SA, Jha V, Ramchandran R, Karihaloo A, Tsiokas L, Chan B, Dhanabal M, Hanai JI, Venkataraman G, Shriver Z, Keiser N, Kalluri R, Zeng H, Mukhopadhyay D, Chen RL, Lander AD, Hagihara K, Yamaguchi Y, Sasisekharan R, Cantley L, Sukhatme VP: Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001, 7:811-822.
56. Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L, Lindahl U, Hohenester E, Timpl R: Structural basis and potential role of heparin/ heparan sulfate binding to the angiogenesis inhibitor endostatin. Embo J 1999, 18:6240-6248.
57. MacDonald NJ, Shivers WY, Narum DL, Plum SM, Wingard JN, Fuhrmann SR, Liang H, Holland-Linn J, Chen DH, Sim BK: Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem 2001, 276:25190-25196.
58. Kim YM, Hwang S, Pyun BJ, Kim TY, Lee ST, Gho YS, Kwon YG: Endostatin blocks VEGF-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem 2002.
59. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, Lombardo C, Pihlajaniemi T, Alitalo K, Vuori K: Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 2001, 98:1024-1029.
60. Wickstrom SA, Alitalo K, Keski-Oja J: Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002, 62:5580-5589.
61. Calvete JJ: Structures of integrin domains and concerted conformational changes in the bidirectional signaling mechanism of alphaIIbbeta3. Exp Biol Med (Maywood) 2004, 229:732-744.
62. Wickstrom SA, Alitalo K, Keski-Oja J: An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 2004, 279:20178-20185.
63. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA: Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 2001, 155:459-470.
64. Furumatsu T, Yamaguchi N, Nishida K, Kawai A, Kunisada T, Namba M, Inoue H, Ninomiya Y: Endostatin Inhibits Adhesion of Endothelial Cells to Collagen I via alpha(2)beta(1) Integrin, a Possible Cause of Prevention of Chondrosarcoma Growth. J Biochem (Tokyo) 2002, 131:619-626.
65. Wickstrom SA, Alitalo K, Keski-Oja J: Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity. J Biol Chem 2003, 278:37895-37901.
66. Lohler J, Timpl R, Jaenisch R: Embryonic lethal mutation in mouse collagen I gene causes rupture of blood vessels and is associated with erythropoietic and mesenchymal cell death. Cell 1984, 38:597-607.